文献速递脑血管病

DEFUSE 3亚组分析:取栓对卒中结局的影响

Association of Thrombectomy With Stroke Outcomes Among Patient Subgroups: Secondary Analyses of the DEFUSE 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2019-01-01

DEFUSE 3随机临床试验的二次分析纳入182例前循环大血管闭塞且灌注影像显示可挽救组织的急性缺血性卒中患者,比较血管内取栓联合内科治疗与单纯内科治疗。校正后取栓改善功能结局的common OR为3.1(95%CI 1.8-5.4),且与年龄、基线NIHSS评分、随机化时间、影像 modality 及闭塞部位均无显著交互作用。

要点

  • 取栓在6-16小时时间窗内对伴可挽救组织的患者普遍获益。
  • 年龄、症状轻重、就诊早晚及闭塞部位不影响取栓疗效。
  • 研究样本量小,需晚期时间窗试验的汇总分析进一步确认。

核心结论

  • 对灌注影像显示可挽救组织的患者,发病至最后已知良好时间16小时内启动血管内取栓可使不同临床特征的患者获益。

研究设计与样本

  • DEFUSE 3为随机、开放标签、盲法终点试验,2016年5月至2017年5月在美国38个中心开展。
  • 296例入组患者中182例符合全部纳入标准并随机,纳入意向性治疗分析。
  • 干预为血管内取栓联合内科治疗对比单纯内科治疗。

主要发现

  • 总体队列中,年轻、较低基线NIHSS评分和较低血清葡萄糖水平是更好功能结局的独立预测因素。
  • 校正上述变量后,血管内治疗改善功能结局的common OR为3.1(95%CI 1.8-5.4)。

关键数值与推荐

  • 主要结局为第90天改良Rankin量表评估的功能结局。
  • 采用多因素有序logistic回归计算校正后的common OR。

临床怎么用

  • 对伴可挽救组织的急性缺血性卒中患者,不应仅因年龄大、症状轻或就诊晚而排除取栓治疗。

局限性

  • 本研究样本量小,需晚期时间窗血管内卒中试验的汇总分析以确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The DEFUSE 3 randomized clinical trial previously demonstrated benefit of endovascular thrombectomy for acute ischemic stroke in the 6- to 16-hour time window. For treatment recommendations, it is important to know if the treatment benefit was universal. OBJECTIVE: To determine the outcomes among patients who may have a reduced effect of thrombectomy, including those who are older, have milder symptoms, or present late. DESIGN, SETTING, AND PARTICIPANTS: DEFUSE 3 was a randomized, open-label, blinded end point trial conducted from May 2016 to May 2017. This multicenter study included 38 sites in the United States. Of 296 patients who were enrolled in DEFUSE 3, 182 patients met all inclusion criteria and were randomized and included in the intention-to-treat analysis, which was conducted in August 2017. These patients had acute ischemic strokes due to an occlusion of the internal carotid artery or middle cerebral artery and evidence of salvageable tissue on perfusion computed tomography or magnetic resonance imaging. The study was stopped early for efficacy. INTERVENTIONS: Endovascular thrombectomy plus medical management vs medical management alone. MAIN OUTCOMES AND MEASURES: Functional outcome at day 90, assessed on the modified Rankin Scale. Multivariate ordinal logistic regression was used to calculate the adjusted proportional association between endovascular treatment and clinical outcome (shift in the distribution of modified Rankin Scale scores expressed as a common odds ratio) among patients of different ages, baseline stroke severities, onset-to-treatment times, locations of the arterial occlusion, and imaging modalities used to document the presence of salvageable tissue (computed tomography vs magnetic resonance imaging). RESULTS: This study included 182 patients (median [interquartile range] age, 70 [59-80] years; median [interquartile range] National Institutes of Health Stroke Scale score, 16 [11-21], and 92 women [51%]). In the overall cohort, independent predictors of better functional outcome were younger age, lower baseline National Institutes of Health Stroke Scale score, and lower serum glucose level. The common odds ratio for improved functional outcome with endovascular therapy, adjusted for these variables, was 3.1 (95% CI, 1.8-5.4). There was no significant interaction between this treatment effect and age (P = .93), National Institutes of Health Stroke Scale score (P = .87), time to randomization (P = .56), imaging modality (P = .49), or location of the arterial occlusion (P = .54). CONCLUSIONS AND RELEVANCE: Endovascular thrombectomy, initiated up to 16 hours after last known well time in patients with salvageable tissue on perfusion imaging, benefits patients with a broad range of clinical features. Owing to the small sample size of this study, a pooled analysis of late time window endovascular stroke trials is needed to confirm these results. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02586415.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Lansberg MG, Mlynash M, Hamilton S, et al. Association of Thrombectomy With Stroke Outcomes Among Patient Subgroups: Secondary Analyses of the DEFUSE 3 Randomized Clinical Trial. JAMA Neurol. 2019. PMID: 30688974. doi:10.1001/jamaneurol.2018.4587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。